Pomalidomide-dexamethasone
Showing 1 - 25 of 2,305
Multiple Myeloma Trial in Beijing, Qingdao (SPD:Selinexor Oral Tablet, Pomalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- SPD:Selinexor Oral Tablet, Pomalidomide, Dexamethasone
-
Beijing, Beijing, China
- +1 more
Jul 26, 2022
Multiple Myeloma Trial in Hackensack (Daratumumab, Pomalidomide, All-trans retinoic acid)
Recruiting
- Multiple Myeloma
- Daratumumab
- +3 more
-
Hackensack, New JerseyJohn Theurer Cancer Center
Jun 10, 2022
Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)
Recruiting
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
-
Afula, Israel
- +7 more
Jul 10, 2022
Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Chicago, IllinoisUniversity of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023
Multiple Myeloma Trial in Seoul (Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Carfilzomib 56 MG [Kyprolis]
- +2 more
-
Seoul, Korea, Republic ofSamsung Medical Center
Aug 19, 2022
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (Daratumumab, Clarithromycin,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +3 more
-
New York, New YorkWeill Cornell Medicine - Multiple Myeloma Center
Jun 8, 2022
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)
Not yet recruiting
- Relapsed Cancer
- +2 more
- Isatuximab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 19, 2023
Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- +4 more
- Isatuximab
- +2 more
-
Chapel Hill, North Carolina
- +2 more
Jun 9, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)
Active, not recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Jan 9, 2023
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Multiple Myeloma Trial in Duarte, Boston, Portland (SL-401/ Pomalidomide/ Dexamethasone)
Terminated
- Multiple Myeloma
- SL-401/ Pomalidomide/ Dexamethasone
-
Duarte, California
- +2 more
Jan 13, 2022
Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)
Not yet recruiting
- Relapsed Refractory Multiple Myeloma
- REGN5458
- +3 more
- (no location specified)
Feb 6, 2023
Plasma Cell Myeloma Trial in Atlanta (Belantamab Mafodotin, Dexamethasone, Pomalidomide)
Recruiting
- Plasma Cell Myeloma
- Belantamab Mafodotin
- +2 more
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Jul 21, 2022
Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Apr 13, 2022
Multiple Myeloma Trial in United States (Pomalidomide, stem cell, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Pomalidomide
- +3 more
-
Basking Ridge, New Jersey
- +9 more
Jan 23, 2023
Non-interventional Study With Pomalidomide (Imnovid®)
Completed
- Multiple Myeloma
-
Freiburg, Baden-Wuerttemberg, GermanyiOMEDICO AG
Aug 11, 2022
Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma Trial in Rochester, Nashville (Dexamethasone, Ixazomib Citrate,
Active, not recruiting
- Plasma Cell Leukemia
- +2 more
- Dexamethasone
- +3 more
-
Rochester, Minnesota
- +1 more
May 19, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022